androgen deprivation therapy (ADT)

From Aaushi
Jump to navigation Jump to search

Introduction

Pharmacologic therapy to diminish circulating levels of androgen, in particular plasma testosterone, through use of:

Indications

Dosage

Monitor

Adverse effects

Complications

Management

More general terms

Additional terms

References

  1. 1.0 1.1 Levine GN et al Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology CA Cancer J Clin. 2010 May-Jun;60(3):194-201 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20124400
    Levine GN et al Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010 Feb 16;121(6):833-40. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20124128
  2. 2.0 2.1 Alibhai SMH et al. Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol 2010 Dec 1; 28:5038. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21041715
  3. 3.0 3.1 FDA MedWatch, 10/20/2010 GnRH Agonists: Label Change - Increased Risk of Diabetes and Cardiovascular Disease (Update) http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm230359.htm
  4. 4.0 4.1 Nguyen PL et al Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate Cancer: A Meta-analysis of Randomized Trials JAMA. 2011;306(21):2359-2366 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22147380 <Internet> http://jama.ama-assn.org/content/306/21/2359.short
    Kelly WK and Gomella LG Androgen Deprivation Therapy and Competing Risks JAMA. 2011;306(21):2382-2383 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22147384 <Internet> http://jama.ama-assn.org/content/306/21/2382.short
  5. 5.0 5.1 Crook JM et al Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy N Engl J Med 2012; 367:895-903September 6, 2012 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22931259 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1201546
    Sartor O. Androgen deprivation -- continuous, intermittent, or none at all? N Engl J Med 2012 Sep 6; 367:945 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22931264
  6. 6.0 6.1 Smith MR et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol 2012 Sep 10; 30:3271 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22649143
  7. 7.0 7.1 Lapi F et al. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer. JAMA 2013 Jul 17; 310:289 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23860987 <Internet> http://jama.jamanetwork.com/article.aspx?articleid=1713592
  8. 8.00 8.01 8.02 8.03 8.04 8.05 8.06 8.07 8.08 8.09 8.10 8.11 Geriatric Review Syllabus, 8th edition (GRS8) Durso SC and Sullivan GN (eds) American Geriatrics Society, 2013
    Geriatric Review Syllabus, 9th edition (GRS9) Medinal-Walpole A, Pacala JT, Porter JF (eds) American Geriatrics Society, 2016
    Geriatric Review Syllabus, 10th edition (GRS10) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2019
  9. Mohile SG, Mustian K, Bylow K, Hall W, Dale W. Management of complications of androgen deprivation therapy in the older man. Crit Rev Oncol Hematol. 2009 Jun;70(3):235-55. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18952456
  10. 10.0 10.1 Ito K et al, Cost-Effectiveness of Fracture Prevention in Men Who Receive Androgen Deprivation Therapy for Localized Prostate Cancer Annals of Internal Medicine 2010, 152:621, May 18, 2010 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/20479027 <Internet> http://www.annals.org/content/152/10/621.abstract
  11. 11.0 11.1 Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist- induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2004 Aug;89(8):3841-6. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15292315
  12. 12.0 12.1 12.2 Medical Knowledge Self Assessment Program (MKSAP) 11, 14, 15 16, 18. American College of Physicians, Philadelphia 1998, 2006, 2009, 2012, 2018.
    Medical Knowledge Self Assessment Program (MKSAP) 19 Board Basics. An Enhancement to MKSAP19. American College of Physicians, Philadelphia 2022
  13. 13.0 13.1 NIH: News & Events. Dec 5, 2013 NIH-funded study shows increased survival in men with metastatic prostate cancer who receive chemotherapy when starting hormone therapy. http://www.nih.gov/news/health/dec2013/nci-05.htm
  14. 14.0 14.1 14.2 Castellino AM Cognitive Impairment Linked to Androgen Deprivation Therapy. Medscape Oncology. May 14, 2015 http://www.medscape.com/viewarticle/844690
    Gonzalez BD et al Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison. American Society of Clinical Oncology. May 11, 2015
  15. Lu-Yao GL; Albertsen PC; Moore DF et al Fifteen-Year Survival Outcomes Following Primary Androgen- Deprivation Therapy for Localized Prostate Cancer. JAMA Intern Med. Published online July 14, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25023796 <Internet> http://archinte.jamanetwork.com/article.aspx?articleid=1887061
    Trinh QD and Schrag D Measuring the Effectiveness of Androgen-Deprivation Therapy for Prostate Cancer in the Medicare Population. Adequate Data Are Neither the Same as Nor the Enemy of Perfect Data. JAMA Intern Med. Published online July 14, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25023522 <Internet> http://archinte.jamanetwork.com/article.aspx?articleid=1887059
  16. Nead KT et al. Androgen deprivation therapy and future Alzheimer's disease risk. J Clin Oncol 2016 Feb 20; 34:566. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26644522 Free Article <Internet> http://jco.ascopubs.org/content/34/6/566
    McGinty HL. Unlocking electronic medical record data to identify possible connections between cancer and cognitive declines. J Clin Oncol 2016 Feb 20; 34:530. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26712232 Free Article <Internet> http://jco.ascopubs.org/content/34/6/530
  17. 17.0 17.1 Nead KT, Gaskin G, Chester C Association Between Androgen Deprivation Therapy and Risk of Dementia. JAMA Oncol. Published online October 13, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27737437 <Internet> http://jamanetwork.com/journals/jamaoncology/article-abstract/2569059
    Walsh CG, Johnson KB Observational Cohort Studies and the Challenges of In Silico Experiments. JAMA Oncol. Published online October 13, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27737433 <Internet> http://jamanetwork.com/journals/jamaoncology/article-abstract/2569057
  18. 18.0 18.1 18.2 18.3 18.4 Alibhai SMH, Zukotynski K, Walker-Dilks C et al Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis. Ann Intern Med. Aug 8, 2017. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28785760 <Internet> http://annals.org/aim/article/2647668/bone-health-bone-targeted-therapies-nonmetastatic-prostate-cancer-systematic-review
    Farooki A, Scher HI Maintaining Bone Health During Hormonal Therapy for Prostate Cancer. Ann Intern Med. Aug 8, 2017. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28785765 <Internet> http://annals.org/aim/article/2648591/maintaining-bone-health-during-hormonal-therapy-prostate-cancer
  19. 19.0 19.1 Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005 Jan 14; 352:154. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/15647578 Free Article <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa041943
  20. Smith MR, Lee WC, Brandman J et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005 Nov 1; 23:7897 PMID: https://www.ncbi.nlm.nih.gov/pubmed/162580
  21. 21.0 21.1 21.2 Jayadevappa R, Chhatre S, Malkowicz B et al Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer. JAMA Netw Open. 2019;2(7):e196562. PMID: https://www.ncbi.nlm.nih.gov/pubmed/31268539 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2737101
    Harding A Long-Term Androgen Deprivation May Boost Alzheimer's, Dementia Risk. Annals of Long-Term Care. DEc 23, 2019 https://www.managedhealthcareconnect.com/content/long-term-androgen-deprivation-may-boost-alzheimers-dementia-risk
    Krasnova A, Epstein M, Marchese M et al Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. Prostate Cancer Prostatic Dis Nov 29, 2019 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31784699 https://www.nature.com/articles/s41391-019-0189-3
  22. 22.0 22.1 Larkin M Loss, Mutation of NCOR2 Likely Fuels Prostate Cancer Progression, Resistance. Medscape. December 23, 2021 https://www.medscape.com/viewarticle/965465
    Long MD, Jacobi JJ, Singh PK et al Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer. Cell Reports 2021. 37(11):110109 https://www.sciencedirect.com/science/article/pii/S221112472101603X